Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
Year : 2014  |  Volume : 10  |  Issue : 1  |  Page : 215-216

Author's Reply

1 Department of Radiotherapy and Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Pathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Date of Web Publication23-Apr-2014

Correspondence Address:
Ritesh Kumar
Department of Radiotherapy and Regional Cancer Centre, Postgraduate Institute of Medical Education and Research, Chandigarh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

How to cite this article:
Kumar N, Kumar R, Bera A, Ghoshal S, Kapoor R, Radotra B D, Sharma SC. Author's Reply. J Can Res Ther 2014;10:215-6

How to cite this URL:
Kumar N, Kumar R, Bera A, Ghoshal S, Kapoor R, Radotra B D, Sharma SC. Author's Reply. J Can Res Ther [serial online] 2014 [cited 2021 Jul 28];10:215-6. Available from: https://www.cancerjournal.net/text.asp?2014/10/1/215/131442


We appreciate the observations and questions raised regarding the article. [1] The questions definitely need a few clarifications and we hope that we would be able to do the same. The series presented by us focused on the clinical outcomes in patients of thymoma per se and mentioned the various paraneoplastic syndromes associated with thymoma. [1] Our series differs from the series by Kumar et al., [2] which focused on the myasthenia gravis patients who underwent thymectomy and on histopathological analysis revealed thymic hyperplasia, thymoma, normal thymus, involuted thymus, thymic cysts, and unremarkable thymus. In our series, the patients with a confirmed histopathological diagnosis of thymoma were analyzed and the patients with hyperplasia, cysts, or carcinoid were not a part of the analysis. Management of the paraneoplastic syndromes was done as per the standard guidelines, while the patients with histopathological diagnosis of thymoma were staged as per Masaoka-Koga staging system and then managed accordingly with surgery as the cornerstone of therapy and further adjuvant treatment in form of radiotherapy and chemotherapy was decided as per stage, histopathology and prognostic features. [3] In locally advanced cases or inoperable cases, a neoadjuvant approach was usedand then the patient was assessed for surgical removal. [4] Thenine patients did not underwent surgery because of locally advanced disease status with poor responseto neoadjuvant therapy and poor surgical suitability but were symptomaticallyimproved with radiotherapy and/or chemotherapy. This is a small and rare series of outcome of thymoma with multimodality approach, so further multivariate analysis was not possible due to small sample size.

 > References Top

1.Kumar N, Kumar R, Bera A, Ghoshal S, Kapoor R, Radotra BD, et al. Thymoma: Clinical experince from a tertiary care institute from North India. J Cancer Res Ther 2013;9:235-9.  Back to cited text no. 1
2.Kumar N, Verma AK, Mishra A, Agrawal G, Agrawal A, Mishra UK, et al. Factors predicting surgical outcome of thymectomy in myasthenia gravis: A 16-year experience. Ann Indian Acad Neurol 2011;14:267-71.  Back to cited text no. 2
[PUBMED]  Medknow Journal  
3.Falkson CB, Bezjak A, Darling G, Gregg R, Malthaner R, Maziak DE, et al. The management of thymoma: A systematic review and practice guideline. J Thorac Oncol 2009;4:911-9.  Back to cited text no. 3
4.Lucchi M, Ambrogi MC, Duranti L, Basolo F, Fontanini G, Angeletti CA, et al. Advanced stage thymomas and thymic carcinomas: Results of multimodality treatments. Ann Thorac Surg 2005;79:1840-4.  Back to cited text no. 4


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article

 Article Access Statistics
    PDF Downloaded38    
    Comments [Add]    

Recommend this journal